Dr. Ivan Foeldvari wurde eingeladen, am 19.11.2024 auf dem Rheumakongrerss November 2024 in Wahington, DC, USA, einen Übersichtsvortrag über die Therapie der juvenillen sysemischen Sklerodermie zu halten.
Congratulations to: Ivan Foeldvari
whose paper has been recognized as a top cited paper* in:
ARTHRITIS CARE & RESEARCH
New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis
*Among work published between 1 January 2022 – 31 December 2023.
ERN ReCONNET Webinars
Rheuma? Das ist doch eine Erkrankung, die ältere Menschen plagt – so denken viele.
Dr. Ivan Foeldvari, Hamburger Zentrum für Kinder- und Jugendrheumatologie, berichtet im Hamburger Ärztemagazin Dezember 2023.
Externer Link zum Beitrag: Auch Kinder können Rheuma haben (PDF)
The result of the International Hamburg Consensus Meeting December 2022
More information:
https://www.tandfonline.com/doi/full/10.1080/1744666X.2023.2298354
Juvenile localized scleroderma, also known as morphea, is an rare condition, it occurs around 1 in 5000 children, where the skin and the tissues underneath the skin like fat tissue, muscle, tendons, and bone, get inflamed and the skin become thickened and harder. To treat this condition, it’s important to have a team of specialists, pediatric rheumatologist (a doctor who specializes in treating kids with joint and autoimmune diseases) and pediatric dermatologist (pediatric skin specialist)
Before starting treatments, we need to understand how active the disease is. We recommend using a tool called LoSCAT to assess the amount and intensity of skin involvement and also look for any signs of most common extracutaneous (not involving the skin) involvement as joint and eyes (white uveitis). This assessment needs to be repeated every 3 to 6 months to judge the treatment effect and assess activity. In the assessment it is sometimes difficult to differentiate between damage and activity of the disease. A main issue is to diagnose the condition quickly and early in the disease course to be able to start treatment before any damage occurs.
Our main goal is to achieve the state of “inactive disease”. We suggest a “treat to target” strategy, it means stepwise escalating treatment till reaching inactive disease, it means no tolerance for active disease. We suggest considering a patient to be in remission while on medication if they have been free of active disease for at least 12 months, and our ultimate aim is to achieve remission without the need for medication. Systemic therapy (treatment that affects the entire body) is needed for all patients, where the lesion crosses a joint and/or any cosmetic change can occur. All systemic therapy has an anti-inflammatory effect, with the aim to stop the inflammatory process.
The first line treatment is a classical disease modifying agents Methotrexate, in a dose (15mg/m2 body surface /week, oral or subcutaneously). If someone can’t tolerate Methorexate , if we still need a medication to keep the disease asleep, we stop Methotexate and switch mycophenolate mofetil. This medicine is orally taken every day. We don’t suggest using hydroxychloroquine, cyclosporine, or anti-TNF as a treatment option. To intensify the treatment effect we apply Methotrexate or Mycophenolate in combination or a combination with more effective anti-inflammatory drug, a biologic DMARD (Tocilizumab or Abatacept both subcutaneously) or targeted synthetic DMARDs(tsDMARDs) . JAK inhibitors, tsDMARDs, are a different category of oral medications, “oral biologics”, may be beneficial if the bDMARDs are ineffective. It is not clear yet, which specific JAK inhibitor is most effective for juvenile localized scleroderma. In extremely severe cases, we might consider using Rituximab after the previous treatment options.
For patients with facial involvement, we suggest autologous fat transplantation to correct the cosmetic changes as early as possible independent of background therapy. Autologous fat transplantation means, that fat cells are subtracted from the upper leg and after a preparation reinjected in the lesion in the face to have anti-inflammatory effect and volume filling effect. This treatment can significantly boost self-esteem/body image and improve the quality of life.
It is an open question the duration of inactive disease on medication before we are considering tapering or stopping the medication. Currently we suggest waiting for at least 24 months of inactive disease on medication before making any changes. If it has been challenging to achieve remission, we recommend reducing the medication dose rather than stopping it. In the future, we hope that more data will give us better guidance regarding more effective control of the disease and the best way when and how wean or discontinue medication.
Ivan Foeldvari 1, Edoardo Marrani 2
1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Am Schön Klinik Eilbek, Dehnhaide 120, 22081
Hamburg, Germany
2Rheumatology Unit, AOU Meyer IRCCS, ERN ReCONNET center, Viale Gaetano Pieraccini 24, 50139
Firenze, Italy
Publication
Systemic therapy in juvenile localized scleroderma
Ivan Foeldvari, Edoardo Marrani
Expert Rev Clin Immunol. 2023 Jul-Dec
Zur Verstärkung des ärztlichen Teams suchen wir Sie, mit abgeschlossener Ausbildung in der Kinder- und Jugendheilkunde für 20 Wochenstunden.
Wir verfügen über eine volle Weiterbildungsbefugnis. Die Arbeitszeit ist von Montag bis Donnerstag 09.00-14.00 Uhr. Wochenend- und Nachtdienste fallen nicht an. Die Vergütung ist übertariflich.
Wir haben eine große Studienambulanz. Das Zentrum ist assoziiert mit dem Asklepios-Campus Hamburg der Semmelweiss Universität in Budapest.
Bei Interesse melden Sie sich bei
Ivan Foeldvari (sprechstunde(at)kinderrheumatologie.de oder 040/2092-3694 oder -3697).
Wir freuen uns auf Sie.
Dr. Ivan Foeldvari war Mitglied der wissenschaftlichen Committee und Vortagende beim ersten Pediatric Rheumatology European Association Educational Kurs für juvenile Sklerodermie (26-28 Oktober 2023).
Vortrag:
A turning point in JIA treatment for the appropriate patient: Exploring tofacitinib’s role: „The current JIA treatment paradigm and unmet needs“
https://www.pres.eu/pres2023/satellite-symposia-meet-the-expert-sessions.html